Analyst Price Targets — MMED
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 28, 2026 12:16 pm | — | UBS | $25.00 | $18.02 | TheFly | MiniMed initiated with a Buy at UBS |
| June 4, 2026 12:01 pm | Matt O'Brien | Piper Sandler | $16.00 | $14.88 | StreetInsider | Piper Sandler on MiniMed Group (MMED): 'Nice Start as a Public Entity but Still Plenty to Prove' |
| June 4, 2026 10:32 am | Larry Biegelsen | Wells Fargo | $22.00 | $14.26 | TheFly | MiniMed price target lowered to $22 from $26 at Wells Fargo |
Latest News for MMED
MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript
MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.
Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organic Advanced global pipeline ahead of schedule with FDA submission for MiniMed Fit™, CE Mark for MiniMed Flex™, Vivera™ FCL U.S. pivotal trial enrollment completion, and IDE approval for next-gen…
MiniMed Group, Inc. (NASDAQ:MMED) will release its first quarter earnings report before the opening bell on Tuesday, Sept. 1.
NORTHRIDGE, Calif., Aug. 25, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MMED.
U.S. House Trading
No House trades found for MMED.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.